<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3423">
  <stage>Registered</stage>
  <submitdate>25/10/2011</submitdate>
  <approvaldate>25/10/2011</approvaldate>
  <nctid>NCT01505803</nctid>
  <trial_identification>
    <studytitle>The Effect of a Nutritional Supplement in Individuals With Type 2 Diabetes Mellitus: a Pilot Study</studytitle>
    <scientifictitle>The Effect of a Nutritional Supplement on Cardiometabolic, Inflammatory, and Oxidative Stress Markers in Individuals With Type 2 Diabetes Mellitus: a Pilot Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>HREC 12392</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <healthcondition>Insulin Resistance</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Zinc supplements
Other interventions - Omega 3 supplements
Other interventions - Placebo supplements

Active Comparator: Zinc supplement - 

Active Comparator: Omega 3 supplement - 

Active Comparator: Zinc and omega 3 supplements - 

Placebo Comparator: Placebo supplement - 


Other interventions: Zinc supplements
Participants will receive 40 mg of zinc each day for 12 weeks.

Other interventions: Omega 3 supplements
Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.

Other interventions: Placebo supplements
Participants will receive placebo supplements each day for 12 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Plasma lipids (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides)</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Glycaemic control (glucose, insulin, HbA1c)</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Inflammation &amp; oxidative stress (CRP, TNF-a, IL-1, IL-2, IL-6, IL-10 F2 isoprostanes, NF-?B, MPO, other)</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Zinc transporter mRNA expression in peripheral blood mononuclear cells</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma zinc</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma fatty acids</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Female, postmenopausal

          -  Type 2 diabetes (controlled by diet and lifestyle; or oral hypoglycaemic medication
             (i.e. metformin) for not more than 7 years)

          -  Normal Glomerular Filtration Rate (GFR) and normal microalbumin/creatine ratio

          -  No nutritional supplements in the 6 weeks prior to the trial &amp; continuing through the
             trial period

          -  Non-smoking</inclusivecriteria>
    <inclusiveminage>48</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Diagnosed with current major illness (renal disease, significant cardiovascular
             disease, gastrointestinal disorders, cancer, or other significant disorder likely to
             interfere with zinc metabolism)

          -  Taking medications that are likely to interfere with zinc metabolism</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>48</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>University of Sydney - Sydney</hospital>
    <postcode>2006 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Diabetes Mellitus (DM) is a major risk factor for cardiovascular disease, with 50% of
      diabetes-associated deaths being attributed to cardiovascular complications. The
      characterising features of DM include: the presence of chronic hyperglycaemia, consequent
      upon decreased secretion or action of insulin; dyslipidaemia; and enhanced levels of
      oxidative stress and inflammation. Zinc and omega 3 polyunsaturated fatty acids have been
      shown to influence each of these outcomes via several mechanisms. This pilot study will
      examine the effect of nutritional supplements containing zinc and omega 3 on these outcomes
      in a population with type 2 DM.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01505803</trialwebsite>
    <publication>Foster M, Petocz P, Samman S. Effects of zinc on plasma lipoprotein cholesterol concentrations in humans: a meta-analysis of randomised controlled trials. Atherosclerosis. 2010 Jun;210(2):344-52. doi: 10.1016/j.atherosclerosis.2009.11.038. Epub 2009 Nov 29.
Foster M, Samman S. Zinc and redox signaling: perturbations associated with cardiovascular disease and diabetes mellitus. Antioxid Redox Signal. 2010 Nov 15;13(10):1549-73. doi: 10.1089/ars.2010.3111. Review.
Foster M, Hancock D, Petocz P, Samman S. Zinc transporter genes are coordinately expressed in men and women independently of dietary or plasma zinc. J Nutr. 2011 Jun;141(6):1195-201. doi: 10.3945/jn.111.140053. Epub 2011 Apr 13.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Samir Samman</name>
      <address>University of Sydney</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>